thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-18 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
The nobelium can then be isolated by exploiting its tendency to form the divalent state, unlike the other trivalent actinides: under typically used elution conditions (bis-(2-ethylhexyl) phosphoric acid (HDEHP) as stationary organic phase and 0.05 M hydrochloric acid as mobile aqueous phase, or using 3 M hydrochloric acid as an eluant from cation-exchange resin columns), nobelium will pass through the column and elute while the other trivalent actinides remain on the column. However, if a direct "catcher" gold foil is used, the process is complicated by the need to separate out the gold using anion-exchange chromatography before isolating the nobelium by elution from chromatographic extraction columns using HDEHP.
Friendly AI are machines that have been designed from the beginning to minimise risks and to make choices that benefit humans. Eliezer Yudkowsky, who coined the term, argues that developing friendly AI should be a higher research priority: it may require a large investment and it must be completed before AI becomes an existential risk. Machines with intelligence have the potential to use their intelligence to make ethical decisions. The field of machine ethics provides machines with ethical principles and procedures for resolving ethical dilemmas. The field of machine ethics is also called computational morality, and was founded at an AAAI symposium in 2005. Geoffrey Hinton has suggested researchers explore instilling human-aligned values, such as compassion, into AI systems as a safeguard, speculating about the possibility of building "maternal instincts" into AI models, so “they really care about people”. Other approaches include Wendell Wallach's "artificial moral agents" and Stuart J. Russell's three principles for developing provably beneficial machines.
Shortly before World War II, Czechoslovakia ceased to exist. Its territory was divided into the Protectorate of Bohemia and Moravia, the newly declared Slovak State and the short-lived Republic of Carpathian Ukraine. While much of former Czechoslovakia came under the control of Nazi Germany, Hungarian forces swiftly overran the Carpathian Ukraine. Hungary annexed some areas (e.g., Southern Slovakia and Carpathian Ruthenia) in the autumn of 1938. Poland reclaimed Zaolzie previously annexed by the Czechs during the Polish-Soviet war in 1920. The Zaolzie region became part of Nazi Germany after the German invasion of Poland in September 1939. The German economy—burdened by heavy militarisation—urgently needed foreign currency. Setting up an artificially high exchange rate between the Czechoslovak koruna and the Reichsmark brought consumer goods to Germans (and soon created shortages in the Czech lands). Czechoslovakia had fielded a modern army of 35 divisions and was a major manufacturer of machine guns, tanks, and artillery, most of them assembled in the Škoda factory in Plzeň. Many Czech factories continued to produce Czech designs until converted to German designs. Czechoslovakia also had other major manufacturing companies. Entire steel and chemical factories were moved from Czechoslovakia and reassembled in Linz (which incidentally remains a heavily industrialized area of Austria).
Sources: en.wikipedia.org
The trivial (non-systematic) name for alkanes is "paraffins". Together, alkanes are known as the "paraffin series". Trivial names for compounds are usually historical artifacts. They were coined before the development of systematic names, and have been retained due to familiar usage in industry. Cycloalkanes are also called naphthenes. Branched-chain alkanes are called isoparaffins. "Paraffin" is a general term and often does not distinguish between pure compounds and mixtures of isomers, i.e., compounds of the same chemical formula, e.g., pentane and isopentane.
Roller chain is ordinarily hooked up using a master link (also known as a "connecting link"), which typically has one pin held by a horseshoe clip rather than friction fit, allowing it to be inserted or removed with simple tools. Chain with a removable link or pin is also known as "cottered chain", which allows the length of the chain to be adjusted. Half links (also known as "offsets") are available and are used to increase the length of the chain by a single roller. Riveted roller chain has the master link (also known as a "connecting link") "riveted" or mashed on the ends. These pins are made to be durable and are not removable.
=== Recurring character descriptions === Racquel (Erinn Hayes) is an attractive supermom whose comfortable relationship with Joel and Sydney rubs Julia the wrong way. Racquel had attempted to kiss Joel in the past, but Joel turned her down. She has one daughter, Harmony, who was best friends with Joel and Julia's daughter, Sydney. For both of their daughters to continue their close relationship, Joel overlooks the situation and pretends the kiss never happened. Katie (Marguerite Moreau) was Crosby's girlfriend, who was putting pressure on Crosby to settle down and start a family. She was unaware of Jasmine and Jabbar until the fifth episode. She ended her relationship with Crosby after he revealed his secret about having a son. Although she was upset that he had been secretly spending time with Jabbar for a month and a half, she was more hurt that he did not introduce Jabbar to her when they met at the recording studio. Dr. Pelikan (Tom Amandes) is the doctor that diagnosed Max Braverman with Asperger's and is giving the family guidance on coping with his condition. Kristina refers Julia to Dr. Pelikan when Julia thinks her daughter may also have Asperger's Syndrome. However, Dr. Pelikan tells Julia that Sydney is gifted and acts out because she is simply bored. In season 5, Hank Rizzoli sees Dr. Pelikan when Hank suspects he has Asperger's Syndrome. Jim Kazinsky (Mike O'Malley) was Sarah's high school sweetheart. Julia sets them up on a date in the series premiere. They have a brief on again, off again relationship in season 1.
Sources: en.wikipedia.org
Dyson joined the faculty at Cornell as a physics professor in 1951, though he still had no doctorate. In December 1952, Oppenheimer, the director of the Institute for Advanced Study in Princeton, New Jersey, offered Dyson a lifetime appointment at the institute, "for proving me wrong", in Oppenheimer's words. Dyson remained at the Institute until the end of his career. In 1957 he became a US citizen. From 1957 to 1961 Dyson worked on Project Orion, which proposed the possibility of space-flight using nuclear pulse propulsion. A prototype was demonstrated using conventional explosives, but the 1963 Partial Test Ban Treaty, in which Dyson was involved and which he supported, permitted only underground nuclear weapons testing, and the project was abandoned in 1965. In 1958 Dyson was a member of the design team under Edward Teller for TRIGA, a small, inherently safe nuclear reactor used throughout the world in hospitals and universities for the production of medical isotopes. In 1966, independently of Elliott H. Lieb and Walter Thirring, Dyson and Andrew Lenard published a paper proving that the Pauli exclusion principle plays the main role in the stability of matter. Hence it is not the electromagnetic repulsion between outer-shell orbital electrons that prevents two stacked wood blocks from coalescing into a single piece, but the exclusion principle applied to electrons and protons that generates the classical macroscopic normal force. In condensed matter physics, Dyson also analysed the phase transition of the Ising model in one dimension and spin waves.
Changes in composition and volumes of luminal fluid. Modification in gastrointestinal motility and consequently transit time of the stomach. Variation in concentration of bile salts and lipids. Loss of drug's matrix integrity due to changes in pH, fat and bile.
Finally, if an employer is insolvent, at common law the insolvency terminates contracts on reasonable notice. To protect pay, under the Fair Entitlements Guarantee Act 2012 the federal government has a scheme for payments to employees whose wages are not otherwise covered.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.